Winter Clinical Dermatology Conference

Timber Pharmaceuticals Meets with FDA on TMB-001 End-of-Phase 2 Trial
February 16, 2022

Timber Pharmaceuticals announced a positive end-of-phase 2 meeting with the FDA about TMB-001 in moderate to severe congenital ichthyosis. Timber also revealed when it plans to start a phase 3 trial.

FDA Approval Gives Dermatologists New Option for Uncontrolled AD
January 18, 2022

The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.

Expert Pearls for Treating Rosacea Patients
January 18, 2022

Treating these patients can be a challenge, but it can also be ‘as easy as pie’ if you follow these tips.

Diagnosing Skin Issues Pose Challenges in SOC
January 18, 2022

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Top Priorities for the AAD: 2022
January 18, 2022

AAD vice president challenges dermatologists to advocate for their patients and themselves.

Answers to Your Patients' Questions on Skin Care
January 17, 2022

Targeting skin care regimens to the individual patient is most likely to yield compliance to a recommended routine.

Poster Aims to Show Improvement in Resident Billing
January 17, 2022

Resident billing can have huge financial implications on academic institutions. A poster from the Icahn School of Medicine at Mount Sinai aimed to assess new medical coding lectures and a modified note template at Winter Clinical Dermatology Conference.

A Good Resource for Molluscum Contagiosum Is Hard to Find
January 17, 2022

More trustworthy sources of information, and data, are needed.

Prevention Is Paramount When Addressing Infectious Diseases
January 17, 2022

As skin manifestations are commonly the first thing spotted with infectious disease, dermatologists are in a great position to counsel patients about prevention.

Biologics Offer Range of Options for Dermatologists Looking to Treat Patients
January 16, 2022

Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.